The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...

People taking weight loss drugs typically start to lose weight within a few weeks. One study, funded by Mounjaro manufacturer ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...